Literature DB >> 16362259

[Effects of irradiation therapy and inhibiting drugs on the pituitary and its adenomas].

W Saeger1.   

Abstract

Radiation therapies of pituitary adenomas induce an increase in fibroses and nuclear pleomorphism. Most growth hormone (GH) secreting pituitary adenomas react to somatostatin analogues by a distinct decrease of GH secretion. In two thirds, levels of IGF-1 can be normalized. Some cases show a shrinkage of adenomas that correlates with fibrosis of the tumor. With these drugs, thyroid stimulating hormone secreting adenomas can also be treated. Prolactin secreting adenomas are mostly treated primarily with dopamine agonists. Up to 90% of cases show a strong decrease in hormone secretion and a distinct shrinkage of the adenomas based on strong decrease in adenoma cell volume. Long-term medication with high doses of glucocorticoids induces Crooke's cells in the anterior pituitary. These are suppressed ACTH cells and characterized by increased numbers of large lysosomes and dense bundles of cytofilaments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16362259     DOI: 10.1007/s00292-005-0809-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  14 in total

Review 1.  Somatostatin analogs in acromegaly.

Authors:  Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

2.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

3.  Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).

Authors:  A Warnet; E Lajeunie; F Gelbert; M Duet; P Chanson; J Cophignon; A G Harris
Journal:  Acta Endocrinol (Copenh)       Date:  1991-04

4.  A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.

Authors:  Cihangir Erem; Arif Hacihasanoglu; Ahmet Sari; Halil Onder Ersöz; Kubilay Ukinç; Sami Fidan
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

5.  Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.

Authors:  U Hamester; W Saeger; D K Lüdecke
Journal:  Histol Histopathol       Date:  1987-04       Impact factor: 2.303

6.  Effects of medical therapy on pituitary tumors.

Authors:  Kalman Kovacs; Eva Horvath
Journal:  Ultrastruct Pathol       Date:  2005 May-Aug       Impact factor: 1.094

7.  Effects of octreotide on morphology of pituitary adenomas in acromegaly.

Authors:  D Sautner; W Saeger; G Tallen; D K Lüdecke; W Rehpenning
Journal:  Pathol Res Pract       Date:  1993-11       Impact factor: 3.250

8.  Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists.

Authors:  H Schottke; W Saeger; D K Lüdecke; J Caselitz
Journal:  Pathol Res Pract       Date:  1986-06       Impact factor: 3.250

9.  Ultrastructural-morphometric effects of radiotherapy on pituitary adenomas in acromegaly.

Authors:  J M Betzold; W Saeger; D K Lüdecke
Journal:  Exp Clin Endocrinol       Date:  1992

10.  Effect of Dopamine Agonists on Lactotroph Adenomas of the Human Pituitary.

Authors:  Lucia Stefaneanu; Kalman Kovacs; Bernd W. Scheithauer; George Kontogeorgos; Darren L. Riehle; Thomas J. Sebo; David Murray; Sergio Vidal; Ami Tran; Michael Buchfelder; Rudolf Fahlbusch
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.